Filing Flows › Nektar Therapeutics (NKTR) › Stock forecast & fair value
Nektar Therapeutics (NKTR) stock forecast and price target
Nektar Therapeutics (NKTR) trades at $37.26. 12 analysts' median price target is $150.00 (+303%), from $50.00 to $192.00.
Nektar Therapeutics' latest quarter
Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for NKTR stock?
The median of 12 analysts' 12-month targets is $150.00, +303% from $37.26; the range is $50.00 to $192.00. The average rating is buy.
Does Nektar Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 75% of the quarters on record.
Is NKTR stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.